Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis in tumor cells, but resistance limits its use.
• Identifying TRAIL sensitizers is crucial for expanding its therapeutic application against various cancers.

Purpose of the Study:

• To investigate the role of c-Met protein in TRAIL sensitivity in brain tumor cells.
• To elucidate the mechanism by which c-Met influences TRAIL-mediated apoptosis.

Main Methods:

• Correlation analysis between c-Met expression levels and TRAIL resistance.
• c-Met knockdown in brain tumor cells and assessment of TRAIL-induced apoptosis.
• Investigation of the interaction between c-Met and death receptor 5 (DR5).
• In vivo studies using immunocompromised mice with engineered brain tumor and stem cell lines.

Main Results:

• A direct correlation was observed between high c-Met expression and TRAIL resistance.
• Knockdown of c-Met, but not its inhibition, sensitized brain tumor cells to TRAIL by disrupting c-Met/DR5 interaction.
• This disruption promoted death-inducing signaling complex (DISC) formation and downstream apoptosis.
• Engineered stem cells expressing secretable TRAIL (S-TRAIL) demonstrated significant anti-tumor effects in mice with c-Met knockdown, TRAIL-resistant brain tumors.

Conclusions:

• c-Met protein contributes to TRAIL resistance in brain tumor cells.
• Targeting c-Met through knockdown can restore TRAIL sensitivity, offering a potential therapeutic strategy.
• This study provides the first evidence of c-Met's role in TRAIL sensitivity for brain tumors, with implications for developing novel brain cancer therapies.